IS7993A - Hreinsunarferli fyrir bakteríu frumuleysi - Google Patents

Hreinsunarferli fyrir bakteríu frumuleysi

Info

Publication number
IS7993A
IS7993A IS7993A IS7993A IS7993A IS 7993 A IS7993 A IS 7993A IS 7993 A IS7993 A IS 7993A IS 7993 A IS7993 A IS 7993A IS 7993 A IS7993 A IS 7993A
Authority
IS
Iceland
Prior art keywords
cellulite
bacterial
purification process
purification
bacterial cellulite
Prior art date
Application number
IS7993A
Other languages
English (en)
Other versions
IS2587B (is
Inventor
Biemans Ralph
Goraj Carine
Mertens Emmanuel
Vandercammen Anne
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305792A external-priority patent/GB0305792D0/en
Priority claimed from GB0305791A external-priority patent/GB0305791D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of IS7993A publication Critical patent/IS7993A/is
Publication of IS2587B publication Critical patent/IS2587B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS7993A 2003-03-13 2005-08-18 Hreinsunarferli fyrir bakteríu frumuleysi IS2587B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305792A GB0305792D0 (en) 2003-03-13 2003-03-13 Purification Process
GB0305791A GB0305791D0 (en) 2003-03-13 2003-03-13 Detoxification process
PCT/EP2004/002641 WO2004081515A2 (en) 2003-03-13 2004-03-11 Purification process for bacterial cytolysin

Publications (2)

Publication Number Publication Date
IS7993A true IS7993A (is) 2005-08-18
IS2587B IS2587B (is) 2010-02-15

Family

ID=32992596

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7993A IS2587B (is) 2003-03-13 2005-08-18 Hreinsunarferli fyrir bakteríu frumuleysi

Country Status (23)

Country Link
US (3) US8084235B2 (is)
EP (1) EP1601689B1 (is)
JP (2) JP4597123B2 (is)
KR (1) KR101052996B1 (is)
CN (1) CN101818185B (is)
AU (2) AU2004219910B2 (is)
BR (1) BRPI0408094A (is)
CA (2) CA2812817C (is)
CY (1) CY1107134T1 (is)
DE (1) DE602004010376T2 (is)
DK (1) DK1601689T3 (is)
EG (1) EG24449A (is)
ES (1) ES2295836T3 (is)
HK (1) HK1086013A1 (is)
IL (1) IL210984A0 (is)
IS (1) IS2587B (is)
MA (1) MA27666A1 (is)
MX (1) MXPA05009579A (is)
NO (1) NO336672B1 (is)
NZ (1) NZ541969A (is)
PT (1) PT1601689E (is)
RU (1) RU2340627C2 (is)
WO (1) WO2004081515A2 (is)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004219910B2 (en) 2003-03-13 2010-06-17 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
KR101523091B1 (ko) 2005-03-23 2015-05-26 오클루스 이노바티브 사이언시즈 인코포레이티드 산화 환원 전위 수용액을 사용한 피부 궤양의 치료 방법
US8431136B2 (en) * 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
JO2813B1 (en) 2005-12-22 2014-09-15 جلاكسو سميث كلاين بايولوجيكالز اس.ايه A vaccine with multiple pneumococcal saccharides
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2007205861B2 (en) 2006-01-20 2013-05-09 Oculus Innovative Sciences, Inc. Methods of treating or preventing sinusitis with oxidative reductive potential water solution
EP2066344B2 (en) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine
PT2144924T (pt) * 2007-04-16 2016-08-17 Minervax Aps Vacina de proteína de fusão
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
PT2167121E (pt) 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
AU2009237647A1 (en) 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
JP5769624B2 (ja) * 2008-08-28 2015-08-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
MX348304B (es) 2009-06-15 2017-06-02 Invekra S A P I De C V Solucion que contiene acido hipocloroso y metodos para usar la misma.
SG10201401516XA (en) 2009-09-03 2014-10-30 Pfizer Vaccines Llc Pcsk9 vaccine
EP3199177A1 (en) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
SI2699587T1 (sl) * 2011-04-22 2019-08-30 Wyeth Llc Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka
US20140072622A1 (en) * 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
CN109289045A (zh) * 2012-09-19 2019-02-01 国立大学法人大阪大学 含有肺炎球菌表面蛋白a的肺炎球菌疫苗
AU2013352723B2 (en) 2012-11-30 2017-01-05 Bioneer Corporation Apparatus for automatically preparing cell-free proteins and method for preparing proteins using same
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
MX371454B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20212335A1 (es) 2014-01-21 2021-12-16 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
RU2743793C1 (ru) 2014-01-21 2021-02-26 Пфайзер Инк. Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
PT3244917T (pt) 2015-01-15 2023-05-31 Pfizer Composições imunogénicas para utilização em vacinas pneumocócicas
US9218427B1 (en) * 2015-01-21 2015-12-22 Maana, Inc. Dynamic semantic models having multiple indices
US10076563B2 (en) * 2015-04-16 2018-09-18 Inventprise, Llc Bordetella pertussis immunogenic vaccine compositions
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
MX2019001341A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de polisacarido neumococico multivalente-proteina.
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
WO2018102818A1 (en) * 2016-12-02 2018-06-07 President And Fellows Of Harvard College Processive template independent dna polymerase variants
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2018280272C1 (en) 2017-06-10 2021-05-06 Inventprise, Inc. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
KR20200051004A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
CA3084436A1 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
BR112020015696A2 (pt) 2018-02-05 2020-12-08 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
AU2019215212A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111989114A (zh) 2018-04-18 2020-11-24 Sk生物科学株式会社 肺炎链球菌的荚膜多糖以及其免疫原性缀合物
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2021021729A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20220144393A (ko) 2020-02-21 2022-10-26 화이자 인코포레이티드 당류의 정제
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
JP2023546615A (ja) 2020-10-27 2023-11-06 ファイザー・インク 大腸菌組成物およびその方法
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
JP3237842B2 (ja) 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
DE4133707A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
GB9216351D0 (en) * 1992-07-31 1992-09-16 Wellcome Found Vaccine production
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
WO1996023061A2 (en) 1995-01-27 1996-08-01 Genencor International, Inc. Surfactant-based enzyme extraction process
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5667786A (en) * 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
KR100619350B1 (ko) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
BR0009163A (pt) * 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
JP4132694B2 (ja) * 2000-03-10 2008-08-13 独立行政法人科学技術振興機構 受容体認識部位が保存された生理活性物質の誘導体及びその使用方法
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
AU2004219910B2 (en) * 2003-03-13 2010-06-17 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process

Also Published As

Publication number Publication date
WO2004081515A2 (en) 2004-09-23
AU2010212257A1 (en) 2010-09-02
US8815254B2 (en) 2014-08-26
WO2004081515A3 (en) 2004-11-11
US20140010843A1 (en) 2014-01-09
US20070026010A1 (en) 2007-02-01
NZ541969A (en) 2008-01-31
JP2010259448A (ja) 2010-11-18
DK1601689T3 (da) 2008-03-25
DE602004010376D1 (de) 2008-01-10
CA2518669C (en) 2014-07-29
AU2004219910B2 (en) 2010-06-17
CN101818185A (zh) 2010-09-01
NO336672B1 (no) 2015-10-19
ES2295836T3 (es) 2008-04-16
RU2340627C2 (ru) 2008-12-10
US20110311577A1 (en) 2011-12-22
IS2587B (is) 2010-02-15
JP4597123B2 (ja) 2010-12-15
CA2518669A1 (en) 2004-09-23
AU2010212257B2 (en) 2012-08-30
CA2812817A1 (en) 2004-09-23
NO20054134D0 (no) 2005-09-06
RU2005125832A (ru) 2006-04-27
MXPA05009579A (es) 2005-11-17
IL210984A0 (en) 2011-04-28
KR101052996B1 (ko) 2011-07-29
AU2004219910A1 (en) 2004-09-23
US8084235B2 (en) 2011-12-27
HK1086013A1 (en) 2006-09-08
JP5683866B2 (ja) 2015-03-11
CA2812817C (en) 2016-12-20
EG24449A (en) 2009-07-13
EP1601689A2 (en) 2005-12-07
MA27666A1 (fr) 2005-12-01
CY1107134T1 (el) 2012-10-24
JP2006520205A (ja) 2006-09-07
PT1601689E (pt) 2008-01-04
CN101818185B (zh) 2016-05-25
NO20054134L (no) 2005-10-04
BRPI0408094A (pt) 2006-02-14
DE602004010376T2 (de) 2008-10-23
US8309327B2 (en) 2012-11-13
EP1601689B1 (en) 2007-11-28
KR20050111357A (ko) 2005-11-24

Similar Documents

Publication Publication Date Title
IS7993A (is) Hreinsunarferli fyrir bakteríu frumuleysi
NO20034941D0 (no) Renseanlegg for varmekraftverk
NO20055459D0 (no) Prosesser
FR2855374B1 (fr) Procede de drageification dure ameliore
GB0209222D0 (en) Purification process
ZA200707236B (en) Microorganisms for therapy
DE602004013124D1 (de) Schleifverfahren
NO20035626D0 (no) Metode
NO20035401D0 (no) Metode
GB0401495D0 (en) Well treatment system
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren
TWI350829B (en) Purification process
FR2857975B1 (fr) Procede de disulfuration des essences
GB0327179D0 (en) Purification method
GB0310752D0 (en) Bioinformatic method
FI20031808A0 (fi) Veden puhdistaminen
FR2864076B1 (fr) Procede de fluorodesazotation
AU2004274039B2 (en) Wastewater purification method
GB0323814D0 (en) Purification of biological macromolecules
GB0314380D0 (en) Purification process
GB0305792D0 (en) Purification Process
AU2003235841A8 (en) Purification system
GB0317218D0 (en) Purification means
SE0301478D0 (sv) New process
SE0302380D0 (sv) New process